HUAIXIANG HAO,Xizhong Huang,Luigi Manenti,Angela Tam
申请号：
US16689157
公开号：
US20200101077A1
申请日:
2019.11.20
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present disclosure relates to pharmaceutical products comprising a combination of (i) a MET inhibitor which is INC280 or a pharmaceutically acceptable salt or hydrate thereof and (ii) an EGFR inhibitor which is an monoclonal antibody such as cetuximab or panitumumab, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments.
